Description

Nikkomycin Z

Nikkomycin Z is a high-purity, antifungal antibiotic and chitin synthase inhibitor used in pharmaceutical research and advanced development of antifungal therapies. As a nucleoside-peptide analog, Nikkomycin Z selectively targets fungal cell wall biosynthesis, offering a unique, non-azole, non-echinocandin mechanism of action with potential applications in systemic mycoses, dermatophytosis, and antifungal combination therapies.

• Selective chitin synthase inhibitor with antifungal activity
• Active against dimorphic fungi including Coccidioides, Histoplasma, and Candida species
• Investigational use in systemic fungal infections and orphan disease indications
• Non-toxic to mammalian cells; favorable preclinical safety profile
• Manufactured under Good Manufacturing Practice (GMP) or research-grade controls
• Supplied with full technical data including Certificate of Analysis (CoA), stability data, and development support

Nikkomycin Z is a nucleoside-peptide antifungal compound produced by Streptomyces tendae. Structurally, it mimics uridine and inhibits fungal chitin synthase enzymes, leading to impaired fungal cell wall formation and lysis without affecting human cell membranes.

In pharmaceutical and preclinical applications, Nikkomycin Z is investigated in:

• Orphan disease treatment programs targeting coccidioidomycosis (Valley Fever) and blastomycosis
• Adjunct antifungal therapy in combination with azoles or echinocandins to improve efficacy and reduce resistance
• Topical and systemic product development for dermatophyte and mold infections
• Broad-spectrum antifungal screening programs in mycology and infectious disease research
• Biodefense and endemic mycosis research pipelines

Nikkomycin Z’s novel mode of action makes it particularly valuable in treating infections resistant to existing antifungals or in populations where azole toxicity or resistance is a concern. Its development is of growing interest in both human and veterinary medicine.

CarboMer supplies Nikkomycin Z in research, pilot, or GMP-intermediate grades, with precise control over peptide integrity, residual fermentation byproducts, and purity. Material is suitable for formulation development, toxicology studies, and IND-enabling research.

Material is packaged in sealed, lyophilized or solid crystalline forms, protected from light and moisture. Custom concentrations or sterile filtration can be provided upon request. Minimum order quantities (MOQ), lead times, and full documentation including CoA and SDS are available for qualifying programs.

Each batch is tested for identity (HPLC, MS), assay (peptide and nucleoside fractions), residual solvents, endotoxins (if applicable), and microbial limits. Development documentation includes analytical methods, characterization data, and handling guidelines.

As with all CarboMer specialty antimicrobials and advanced research compounds, Nikkomycin Z is supported by regulatory consulting, custom sourcing, and formulation development support to accelerate antifungal innovation from lab to clinic.